Sanofi reports further positive data for alemtuzumab
Sanofi SA has reported further positive data for the candidate multiple sclerosis treatment, alemtuzumab, this time from a Phase 3 trial in patients with relapsing-remitting MS who had relapsed while on therapy. The comparator was Rebif.